Intrauterine lesions requiring hysteroscopic surgery
Conditions
Interventions
Anruikefen group:Ciprofol 0.6 mg/kg and a test dose of Anruikefen were administered intravenously in sequence. The starting dose of Anruikefen was 0.7 µg/kg. The dose of Anruikefen for the next patien
Sponsors
Guangzhou Women and Children's Medical Center Liuzhou Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients aged over 18 years, with ASA physical status I–III, undergoing elective or ambulatory hysteroscopic surgery.
Exclusion criteria
Exclusion criteria: 1.Patients who do not consent to participate in the clinical study; 2.Allergy to opioids or local anesthetics; 3.Patients with chronic pain requiring preoperative chronic opioid analgesic use; 4.A history of dementia, psychosis, or other central nervous system diseases; 5.Patients in poor general condition with a history of severe cardiovascular, respiratory, digestive, urinary system diseases, or other comorbidities; 6.Patients who have experienced any of the following conditions within 12 months prior to surgery: myocardial infarction, severe/unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism; 7.Patients unable to cooperate with follow-up or with poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laryngeal mask insertion success status;Adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate and MAP; | — |
Countries
China
Contacts
Public ContactWang Lingyu
Guangzhou Women and Children's Medical Center Liuzhou Hospital
Outcome results
None listed